Delving into the Latest Updates on Tangdu Hospital with Synapse

An Open-label, Multicenter, Randomized Clinical Trial for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract: Washed Microbiota Transplantation Via Mid-gut Tube Versus Colonic Transendoscopic Enteral Tube

This is a prospective, randomized, multicenter study to evaluate WMT in improving nutritional status in malnourished patients who underwent nonphysiological reconstruction of the upper gastrointestinal tract. In this multicenter trial, sixty-two patients will be enrolled in forteen Chinese sites. Participants will be randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic TET. After WMT, each participant will receive free diet plus home enteral nutrition. Home enteral nutrition should last for 2 months at home, with blood, urine and stool samples taken and stored at baseline and 2 months after WMT.

开始日期2024-10-20

申办/合作机构

兰州大学

[+9]

NCT06663059 / Recruiting临床2期IIT

A Prospective, Multicenter, Exploratory Study Comparing 2 Cycles Versus 4 Cycles of Adebrelimab Combined With Chemotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.

开始日期2024-10-01

申办/合作机构

Tangdu Hospital

NCT06485557 / Not yet recruiting临床3期IIT

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

This study uses a prospective cohort design.Subjects are randomly divided into three groups (A, B, C) before surgery. Group A gets 3 cycles of sintilimab + chemo, Group B gets 2 cycles + 1 cycle, and Group C gets 1 cycle + 2 cycles.
Non-squamous NSCLC subjects receive pemetrexed/albumin paclitaxel + platinum, while squamous NSCLC subjects get albumin paclitaxel + platinum.

开始日期2024-08-01

申办/合作机构

Tangdu Hospital

100 项与 Tangdu Hospital 相关的临床结果

登录后查看更多信息

0 项与 Tangdu Hospital 相关的专利（医药）

登录后查看更多信息

802

项与 Tangdu Hospital 相关的文献（医药）

2024-12-31·Virtual and Physical Prototyping

3D-printed biodegradable polycaprolactone rib implants with tissue-specific mechanical properties promote chest wall recovery by stimulating tissue fibrosis

作者: Liang, Xiao ; Yan, Xiaolong ; He, Jiankang ; Meng, Zijie ; Yang, Shangyuan ; Li, Dichen ; Li, Xinyu ; Yin, Feiyang ; Wang, Lei

2024-12-01·Pharmacognosy Magazine

Molecular Targets and Mechanisms of Poria cocos-Licorice Drug Pair for the Treatment of Henoch–Schönlein Purpura Nephritis Based on Network Pharmacology

作者: Liu, Jiahua ; Liu, Qingqing ; Ma, Xiaoqin ; Mi, Jie ; Guo, Weiyan

Background The herbal Poria cocos-Liquorice drug pair (PLDP) possesses the ability to be a diuretic, stimulating the spleen and benefiting the kidney, which plays an important role in the treatment of Henoch–Schönlein purpura nephritis (HSPN). However, the mechanism of action is unknown. Objectives Through the method of network pharmacology, this research sought to determine the mechanism of PLDP against HSPN. Materials and Methods The screening of active ingredients in PLDP was conducted by Traditional Chinese Medicine Systems Pharmacology (TCMSP) databases, while their targets were obtained from the TCMSP and Swiss Target Prediction (STP) databases. The genes of HSPN were searched by OMIM, DisGeNET, and GeneCards databases. Then, the common targets of active ingredients in PLDP and HSPN were mapped by Venn analysis. To get the main targets, the researchers utilized the STRING database to construct the protein–protein interaction (PPI) network of the common targets. Then, the function of gene ontology (GO) and the enrichment of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of the main targets were examined on the Metascape database to identify the molecular mechanism of PLDP against HSPN. The most relevant signaling pathways with HSPN screened from the top 20 pathways were defined as the key pathways. Finally, the “active ingredient-main target-key pathway” network was built in order to identify the core targets and key active ingredients of PLDP against HSPN. Results There were 101 active ingredients and 360 targets for PLDP. One hundred and fifty-seven genes for HSPN and 35 common targets between PLDP and HSPN were identified. Through the “active ingredient-main target-key pathway” network, quercetin, kaempferol, polyporenic acid C, dehydrotumulosic acid, poricoic acid A, and naringenin were identified as key active ingredients; TNF, NOS3, RELA, AKT1, ICAM1, and IFNG were identified as core targets; and the key pathways include TNF signaling pathways, HIF-1 signaling pathways, and IL-17 signaling pathways. Conclusion The research initially investigated the pathways, active ingredients, and targets involved in PLDP against HSPN. The mechanism appears to be linked to its immunomodulatory and anti-inflammatory properties, thus establishing a scientific foundation for further investigation.

2024-12-01·Computational and Structural Biotechnology Journal

Aluminum chloride and D-galactose induced a zebrafish model of Alzheimer's disease with cognitive deficits and aging

Article

作者: Luo, Li ; Yan, Tao ; Yang, Le ; Zhao, Minggao

Alzheimer's disease (AD) is an age-related neurodegenerative disorder. Transgenic and pharmacological AD models are extensively studied to understand AD mechanisms and drug discovery. However, they are time-consuming and relatively costly, which hinders the discovery of potential anti-AD therapeutics. Here, we established a new model of AD in larval zebrafish by co-treatment with aluminum chloride (AlCl₃) and D-galactose (D-gal) for 72 h. In particular, exposure to 150 μM AlCl₃ + 40 mg/mL D-gal, 200 μM AlCl₃ + 30 mg/mL D-gal, or 200 μM AlCl₃ + 40 mg/mL D-gal successfully induced AD-like symptoms and aging features. Co-treatment with AlCl₃ and D-gal caused significant learning and memory deficits, as well as impaired response ability and locomotor capacity in the plus-maze and light/dark test. Moreover, increased acetylcholinesterase and β-galactosidase activities, β-amyloid 1-42 deposition, reduced telomerase activity, elevated interleukin 1 beta mRNA expression, and enhanced reactive oxygen species production were also observed. In conclusion, our zebrafish model is simple, rapid, effective and affordable, incorporating key features of AD and aging, thus may become a unique and powerful tool for high-throughput screening of anti-AD compounds in vivo.

100 项与 Tangdu Hospital 相关的药物交易

登录后查看更多信息

100 项与 Tangdu Hospital 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

临床1期

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CD19-BCMA Targeted CAR-T(Tangdu Hospital) ( BCMA x CD19 )	重症肌无力更多	临床1期
GAP-14 ( DNAJC1 )	胶质瘤更多	临床前
Anti-EPCAM CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) ( EpCAM )	EpCAM阳性实体瘤更多	无进展
Anti-TM4SF1-CAR-T-cell therapy (Shanghai Biomed-union Biotechnology) ( TM4SF1 )	晚期恶性实体瘤更多	无进展